| 51 |
32797900 | Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry. | 2020 Oct 1 |
1 |
| 52 |
32900698 | PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness. | 2020 Sep |
1 |
| 53 |
32994187 | Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. | 2020 Dec |
1 |
| 54 |
33163625 | LINAGLIPTIN-INDUCED PANCREATITIS. | 2020 Jan-Feb |
1 |
| 55 |
33224612 | Evaluation of the use of sitagliptin for insulin resistance in burn patients. | 2020 |
2 |
| 56 |
33239410 | Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. | 2020 Dec 7 |
1 |
| 57 |
33256016 | Sitagliptin Modulates the Response of Ovarian Cancer Cells to Chemotherapeutic Agents. | 2020 Nov 26 |
2 |
| 58 |
29883070 | Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial. | 2019 Mar |
1 |
| 59 |
30242726 | The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. | 2019 Mar |
1 |
| 60 |
30346099 | A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. | 2019 Feb |
1 |
| 61 |
30393950 | Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. | 2019 Apr |
1 |
| 62 |
30475594 | Hollow-Core-Photonic-Crystal-Fiber-Based Miniaturized Sensor for the Detection of Aggregation-Induced-Emission Molecules. | 2019 Jan 2 |
2 |
| 63 |
30609212 | Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. | 2019 May |
1 |
| 64 |
30775811 | Natural compounds with DPP-4 inhibitory effects: Implications for the treatment of diabetes. | 2019 Feb 18 |
1 |
| 65 |
31018682 | Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? | 2019 Jul |
1 |
| 66 |
31019154 | Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones. | 2019 May 28 |
1 |
| 67 |
31019624 | Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study. | 2019 May |
1 |
| 68 |
31105821 | Sitagliptin protects against hypoxia/reoxygenation (H/R)-induced cardiac microvascular endothelial cell injury. | 2019 |
1 |
| 69 |
31148332 | Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial. | 2019 Oct |
1 |
| 70 |
31164243 | DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice. | 2019 Aug |
2 |
| 71 |
31182338 | Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. | 2019 Aug |
1 |
| 72 |
31217853 | Sitagliptin ameliorates advanced glycation end-product (AGE)-induced degradation of extracellular matrix in human primary chondrocytes. | 2019 |
1 |
| 73 |
31219248 | Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. | 2019 Oct |
1 |
| 74 |
31243210 | Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha. | 2019 Oct 1 |
1 |
| 75 |
31275243 | DPP-4 Inhibition and the Path to Clinical Proof. | 2019 |
1 |
| 76 |
31290617 | Sitagliptin promotes mitochondrial biogenesis in human SH-SY5Y cells by increasing the expression of PGC-1α/NRF1/TFAM. | 2019 Oct |
2 |
| 77 |
31336466 | Prevalence and association of co-morbidities in diabetic patients along with prescription patterns in Delhi-NCT, India. | 2019 Mar - Apr |
1 |
| 78 |
31344887 | Solid-State Characterization of Different Crystalline Forms of Sitagliptin. | 2019 Jul 24 |
1 |
| 79 |
31444259 | DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. | 2019 Aug 22 |
2 |
| 80 |
31543976 | Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery. | 2019 |
1 |
| 81 |
28892258 | Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY. | 2018 Mar |
2 |
| 82 |
28931178 | The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha. | 2018 Jun |
1 |
| 83 |
29072800 | Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery. | 2018 Apr |
1 |
| 84 |
29138226 | Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challenge. | 2018 Apr 1 |
2 |
| 85 |
29144805 | DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY. | 2018 Jan |
1 |
| 86 |
29199201 | Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial). | 2018 Jun 1 |
2 |
| 87 |
29208515 | Effectiveness of sitagliptin in a patient with late dumping syndrome after total gastrectomy. | 2018 Apr - Jun |
1 |
| 88 |
29270818 | The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. | 2018 May |
2 |
| 89 |
29275488 | The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial. | 2018 Aug |
2 |
| 90 |
29330813 | Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. | 2018 Feb |
1 |
| 91 |
29402270 | Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE). | 2018 Feb 5 |
1 |
| 92 |
29478970 | Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. | 2018 Feb 25 |
1 |
| 93 |
29511780 | Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. | 2018 May |
1 |
| 94 |
29524519 | SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma. | 2018 May 1 |
3 |
| 95 |
29654643 | Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? | 2018 Aug |
6 |
| 96 |
29655980 | Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes. | 2018 Jun 1 |
1 |
| 97 |
29679391 | Cardiovascular effects of sitagliptin - An anti-diabetes medicine. | 2018 Jul |
1 |
| 98 |
29740221 | Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. | 2018 |
1 |
| 99 |
29770541 | Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus. | 2018 Sep |
1 |
| 100 |
29936573 | Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials. | 2018 Aug |
1 |